Searched for
PARENTERALS LTD
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Quant Small Cap Fund exits HDFC Bank, Jio Financial Services and 5 other stocks in AprilQuant Small Cap Fund reshuffled its portfolio in April, exiting seven stocks including HDFC Bank and Jio Financial Services while adding ne...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- Bio Medica Laboratories shares to debut today. Here's what GMP suggests ahead of listingBio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Bio Medica Laboratories IPO: Check GMP, price band, subscription and other detailsBio Medica Laboratories' initial public offering begins subscription on Thursday. The company plans to raise Rs 52.43 crore through its IPO...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- Mutual funds deploy Rs 1,878 crore across 4 IPOs in March. Check detailsMutual funds invested Rs 1,878 crore across four IPOs in March, led by Sedemac Mechatronics and Central Mine Planning & Design Institute. T...
- Sai Parenterals shares list at 3% premium to IPO price on BSE, NSESai Parenterals made its debut on Dalal Street with a slight uptick in share prices. Despite the company’s promising diversification in pha...
- Sai Parenteral’s IPO allotment likely today: Check status, GMP, other detailsSai Parenteral's IPO share allotment is expected today, with investors able to check their status on BSE or the registrar's website. The is...
- Sai Parenteral IPO Day 3: 43% subscribed; here’s a look at GMP and key details; Should you invest?Sai Parenteral IPO saw 43% subscription on Day 3, with strong NII interest but weak retail participation. Despite no GMP indicating a flat ...
- Sai Parenteral IPO Day 2: Issue booked 41%; check GMP and other details. Should you apply?Sai Parenteral Limited's initial public offering is underway. The IPO ended Day 2 with over 41% subscription. The company aims to raise Rs ...
- Sai Parenteral’s IPO: Issue subscribed just 4% on day 1. Check price band, GMPSai Parenteral’s IPO opened with weak demand, subscribing just 4% on day one amid no grey market premium. While retail and NII interest rem...
- Rs 409 crore Sai Parenteral’s IPO issue opens for subscription. Check price band, GMP and to subscribe or notSai Parenteral's IPO opens for subscription, aiming to raise Rs 409 crore through a mix of fresh equity and an offer for sale. The company ...
- Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore dealEris Lifesciences is set to fully acquire its injectable unit, Swiss Parenterals. The deal involves a share swap valued at Rs 423.3 crore. ...
- Eris acquires 51 pc stake in Swiss Parenterals for Rs 637.5 crEris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...
- Bharat Parenterals gets DCGI nod for favipiravir oral suspensionThe company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parente...
- Parenteral Drugs to sell unit to Fresenius Kabi for Rs 200 crParenteral Drugs today said its subsidiary, Goa Formulations has entered into an agreement with Fresenius Kabi India to sell its manufactur...
- Dishman acquires Creapharm Parenterals for undisclosed amountDishman Pharma and Chemicals today said its Switzerland-based subsidiary has acquired Creapharm Parenterals for an undisclosed amount.
Load More
